Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
NCT ID: NCT00233610
Last Updated: 2011-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
180 participants
INTERVENTIONAL
2003-12-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Casodex - Nolvadex Combination
NCT00637871
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00590213
Open Label Arimidex in Gynecomastia
NCT00241436
Gynecomastia Extension Study
NCT00637182
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bicalutamide
Tamoxifen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced prostate cancer patients suitable for Casodex 150 mg monotherapy
Exclusion Criteria
* No metastatic disease (M1).
* No presence of gynaecomastia and/or mastalgia at screening
* No therapy with medications able to provoke gynaecomastia and/or mastalgia within 6 months of trial entry.
18 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astra Zeneca
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Bari, BA, Italy
Research Site
Bologna, BO, Italy
Research Site
Catania, CT, Italy
Research Site
Bagno a Ripoli, FI, Italy
Research Site
Florence, FI, Italy
Research Site
Genova, GE, Italy
Research Site
Pisa, PI, Italy
Research Site
Parma, PR, Italy
Research Site
Roma, Roma, Italy
Research Site
Udine, UD, Italy
Research Site
Como, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7054IT/0003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.